Drug Profile
Research programme: sirtuin activators - Sirtris
Alternative Names: SRT 1720; SRT 2172; SRT2183Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Sirtris Pharmaceuticals
- Developer Sirtris
- Class Small molecules
- Mechanism of Action SIRT1 protein stimulants; Sirtuin stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Amyotrophic lateral sclerosis; Cancer; Chronic obstructive pulmonary disease; Huntington's disease; Inflammation; Neurological disorders; Type 2 diabetes mellitus
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in USA (Intranasal)